A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A legfontosabb adatok
- Ki végzi
- National Cancer Institute (NCI)
- Hol
- Akron, Albany, Albuquerque, Allentown, Anaheim, Anchorage, Ann Arbor, Arroyo Grande, Asheville, Atlanta, Aurora, Austin, Baltimore, Bangor, Battle Creek, Bellevue, Bellflower, Bethesda, Birmingham, Boise, Boston, Bridgeport, Brooklyn, Burlington, Carson City, Chapel Hill, Charleston, Charlotte, Chicago, Cincinnati, Cleveland, Columbia, Columbus, Corpus Christi, Dallas, Danville, Dayton, Dearborn, Denver, Des Moines, Detroit, Downey, Duarte, Durham, East Lansing, El Paso, Falls Church, Fargo, Fontana, Fort Myers, Fort Worth, Gainesville, Grand Rapids, Green Bay, Greenville, Hackensack, Hartford, Henderson, Hershey, Hollywood, Honolulu, Houston, Indianapolis, Iowa City, Jackson, Jacksonville, Kalamazoo, Kansas City, Kingman, Knoxville, Las Vegas, Lebanon, Lexington, Little Rock, Loma Linda, Long Beach, Los Angeles, Louisville, Lubbock, Madera, Madison, Martinsburg, Maywood, Mesa, Milwaukee, Mineola, Minneapolis, Mobile, Morgantown, Morristown, Muskegon, Nashville, New Brunswick, New Hyde Park, New Orleans, New York, Newark, Niles, Norfolk, Norton Shores, Oakland, Oklahoma City, Omaha, Orange, Orlando, Pahrump, Palo Alto, Parkersburg, Paterson, Pensacola, Peoria, Philadelphia, Phoenix, Pittsburgh, Portland, Providence, Reed City, Reno, Renton, Richmond, Rochester, Royal Oak, Sacramento, Saint Joseph, Salt Lake City, San Antonio, San Diego, San Francisco, Savannah, Scarborough, Seattle, Sioux Falls, Spokane, St Louis, St. Petersburg, Stony Brook, Sylvania, Syracuse, Tacoma, Tampa, The Bronx, Toledo, Torrance, Traverse City, Troy, Tucson, Tulsa, Washington D.C., West Palm Beach, Wilmington, Winston-Salem, Wyoming és Yakima (Egyesült Államok)Mind a 213 helyszín megnézéseMég 3 másik országban, 16 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 461 fő, tervezett
- Kezdés
- 2020. dec. 17.
- Várható befejezés
- 2028. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó, 9 csoport
- A vizsgált kezelések
- 3-Dimensional Conformal Radiation Therapy
- Asparaginase Erwinia chrysanthemi
- Biospecimen Collection
- Blinatumomab
- Bone Marrow Aspiration
- Bone Marrow Biopsy
- Calaspargase Pegol
- Cytarabine
- Dexamethasone
- Hydrocortisone Sodium Succinate
- Lumbar Puncture
- Mercaptopurine
- Methotrexate
- Nivolumab
- Pegaspargase
- Vincristine Sulfate
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan 1–30 év közötti gyermekeket és fiatalokat keres, akiknek a B-sejtes akut limfoblasztos leukémiája (B-ALL) először tért vissza. Down-szindrómás betegek is részt vehetnek.
- Életkor
- 1 évtől 30 évig
- Nem
- Minden nem
- A betegség stádiuma
- CD19-pozitív B-ALL első kiújulása. A kiújult daganatsejteken meg kell lennie a CD19-nek. A kiújulás lehet a csontvelőben, a központi idegrendszerben vagy a herékben.
- Korábbi kezelés
- Fel kell épülni a korábbi kemoterápia, immunterápia vagy sugárkezelés mellékhatásaiból. Korábban nem lehetett őssejt-átültetése. Korábbi blinatumomab vagy CD19 CAR-terápia megengedett, ha a kiújult sejteken még van CD19.
- Biomarker vagy leletérték
- A leukémiasejteken CD19-nek kell lennie.
A részvétel fő kizáró okai
- B-limfoblasztos limfóma, Burkitt-leukémia/limfóma vagy kevert fenotípusú akut leukémia
- Philadelphia-kromoszóma-pozitív B-ALL vagy ABL osztályú Ph-szerű B-ALL
- Aktív, nem kontrollált fertőzés, vagy nem kontrollált HIV-, hepatitis B- vagy hepatitis C-fertőzés
- Aktív vagy feltételezett autoimmun betegség (néhány enyhe forma megengedett), vagy súlyos idegrendszeri betegség, amely kizárja a blinatumomabot
- Csontvelő-elégtelenséggel járó szindróma, például Fanconi-anémia
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Patients must be >= 1 and < 31 years at time of enrollment
- Patients must have first relapse of CD19+ B-ALL (relapse blasts must express CD19) in one of the following categories:; Isolated bone marrow relapse; Isolated central nervous system (CNS) (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse; Combined bone marrow with extramedullary relapse in the CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testes
- Patients with Down syndrome (DS) are eligible in the following categories:; Isolated bone marrow relapse; Combined bone marrow with CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
- Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age; Of note, for patients with developmental delay (e.g., Down syndrome) regardless of age, Lansky scale may be substituted for Karnofsky scale. However, the requirement for ECOG 0-2 remains, regardless of known history of developmental delay
- Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study; Patients with prior blinatumomab or CD19+ chimeric antigen receptor therapy in the upfront setting will be eligible, provided relapsed lymphoblasts retain CD19 expression; Patients must not have had a prior hematopoietic stem cell transplant; A single intrathecal chemotherapy at the time of relapse will be allowed. If < 7 days have elapsed between this intrathecal therapy (IT) and the start of protocol therapy, then the day 1 intrathecal chemotherapy (i.e. methotrexate, cytarabine, or triple intrathecal) may be omitted; In the 28 days prior to enrollment, up to five days of post-relapse, pre-enrollment therapy (steroids and/or hydroxyurea only) is permissible; Patients with Down syndrome who received pre-enrollment therapy and have a white blood count (WBC) >= 30,000/ul at the time of enrollment still must receive protocol specified cytoreductive therapy with vincristine and dexamethasone, and no "washout" is required; Patients with Down syndrome who received pre-enrollment therapy and have a WBC < 30,000/ul at the time of enrollment must be given a 24 hour "washout" before starting immunotherapy; Note: There is no waiting period or "washout" for patients who relapse while receiving upfront therapy
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m\^2 OR a serum creatinine based on age/sex as follows (within 7 calendar days prior to enrollment):; Age: Maximum serum creatinine (mg/dL); 1 to < 2 years: 0.6 (male), 0.6 (female); 2 to < 6 years: 0.8 (male), 0.8 (female); 6 to < 10 years: 1 (male), 1 (female); 10 to < 13 years: 1.2 (male), 1.2 (female); 13 to < 16 years: 1.5 (male), 1.4 (female); >= 16 years: 1.7 (male), 1.4 (female); The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the Center for Disease Control (CDC)
- Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by echocardiogram, cardiac magnetic resonance imaging (MRI) or radionuclide angiogram
- No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Ki nem vehet részt
- Patients with active, uncontrolled infection defined as:; Positive bacterial blood culture within 48 hours of study enrollment; Receiving IV or PO antibiotics for an infection with continued signs or symptoms. Note: Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection if cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved. For patients with clostridium (C.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline; Fever above 38.2 degrees Celsius (C) within 48 hours of study enrollment with clinical signs of infection. Fever without clinical signs of infection that is attributed to tumor burden is allowed if blood cultures are negative for > 48 hours; A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection; Active viral or protozoal infection requiring IV treatment
- Patients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome are not eligible
- Patients with uncontrolled HIV, hepatitis B, or hepatitis C infection. Of note, patients with known human immunodeficiency virus (HIV) infection on effective anti-retroviral therapy with undetectable viral load for at least the last 6 months prior to enrollment are eligible. Similarly, hepatitis B and hepatitis C positive patients who have been treated and have no viral detectable burden are also eligible
- Patients with significant central nervous system pathology that would preclude treatment with blinatumomab, including history of severe neurologic disorder or autoimmune disease with CNS involvement; Note: Patients with a history of seizures that are well controlled on stable doses of anti-epileptic drugs are eligible Patients with a history of cerebrovascular ischemia/hemorrhage with residual deficits are not eligible. Patients with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved
- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained within 7 days prior to enrollment. Patients who are sexually active and of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of this study. Men with female partners of childbearing potential should use effective contraception during the duration of their treatment. The effect of blinatumomab on fertility has not been evaluated. Blinatumomab is not recommended for pregnant women or women of childbearing potential (WOCBP) not using contraception. Females of reproductive potential must use effective contraception during treatment and for at least 48 hours after the last dose of blinatumomab. Studies in animal models have shown that nivolumab can adversely impair pregnancy. Thus, nivolumab is expected to cause fetal harm during pregnancy. WOCBP receiving nivolumab must continue contraception for a period of at least 5 months after the last dose of nivolumab. It is unknown whether nivolumab is present in breast milk, thus breastfeeding should be discontinued while a patient is receiving nivolumab
- Lactating females are not eligible unless they agree to not breastfeed their infants. It is unknown whether blinatumomab or its metabolites are excreted in human breast milk. Women are not permitted to breastfeed while receiving blinatumomab and for the last 48 hours after the last blinatumomab dose. Due to the potential for serious adverse reactions in the breastfed infant, women are not permitted to breastfeed during treatment and for 5 months after the last nivolumab dose
- Patients with known Charcot-Marie-Tooth disease
- Patients with an active known/suspected autoimmune disease are not eligible. However, patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
- Patients with DS patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are not eligible; Note: Group 3 and 4 patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are eligible if this is NOT the only site of relapsed disease
- Patients with B-lymphoblastic lymphoma (B-LLy)
- Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia
- Patients with Philadelphia chromosome positive (Ph+) B-ALL or ABL class Ph-like B-ALL (i.e. rearrangements involving ABL1, ABL2, CSF1R or PDGFRB and predicted to be sensitive to imatinib or dasatinib)
- Patients with mixed phenotype acute leukemia (MPAL)
- Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 1 és 30 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
Még 3 másik országban, 16 helyszínen
- Children's Hospital Medical Center of AkronAkron, Egyesült ÁllamokContact: Lauren R. Draper (principal investigator)Résztvevőt keres
- Albany Medical CenterAlbany, Egyesült ÁllamokContact: Lauren R. Weintraub (principal investigator)Résztvevőt keres
- Presbyterian HospitalAlbuquerque, Egyesült ÁllamokContact: Beeling Armijo (principal investigator)Résztvevőt keres
- Lehigh Valley Hospital-Cedar CrestAllentown, Egyesült ÁllamokContact: Jacob A. Troutman (principal investigator)Résztvevőt keres
- Kaiser Permanente-AnaheimAnaheim, Egyesült ÁllamokNo longer taking part
- Providence Alaska Medical CenterAnchorage, Egyesült ÁllamokContact: Brenda J. Wittman (principal investigator)Résztvevőt keres
- C S Mott Children's HospitalAnn Arbor, Egyesült ÁllamokContact: Joshua W. Goldman (principal investigator)Résztvevőt keres
- PCR OncologyArroyo Grande, Egyesült ÁllamokNo longer taking part
- Mission HospitalAsheville, Egyesült ÁllamokContact: Douglas J. Scothorn (principal investigator)Résztvevőt keres
- Children's Healthcare of Atlanta - Arthur M Blank HospitalAtlanta, Egyesült ÁllamokContact: Waitman K. Aumann (principal investigator)Résztvevőt keres
- Children's Hospital ColoradoAurora, Egyesült ÁllamokContact: Kelly E. Faulk (principal investigator)Résztvevőt keres
- Dell Children's Medical Center of Central TexasAustin, Egyesült ÁllamokContact: Shannon M. Cohn (principal investigator)Résztvevőt keres
- Johns Hopkins University/Sidney Kimmel Cancer CenterBaltimore, Egyesült ÁllamokContact: Stacy L. Cooper (principal investigator)Résztvevőt keres
- Sinai Hospital of BaltimoreBaltimore, Egyesült ÁllamokContact: Jason M. Fixler (principal investigator)Résztvevőt keres
- Eastern Maine Medical CenterBangor, Egyesült ÁllamokRésztvevőt keres
- Bronson Battle CreekBattle Creek, Egyesült ÁllamokNo longer taking part
- Overlake Medical CenterBellevue, Egyesült ÁllamokNo longer taking part
- Kaiser Permanente-BellflowerBellflower, Egyesült ÁllamokNo longer taking part
- Walter Reed National Military Medical CenterBethesda, Egyesült ÁllamokNo longer taking part
- Children's Hospital of AlabamaBirmingham, Egyesült ÁllamokContact: Matthew A. Kutny (principal investigator)Résztvevőt keres
- Saint Luke's Cancer Institute - BoiseBoise, Egyesült ÁllamokContact: Martha M. Pacheco (principal investigator)Résztvevőt keres
- Tufts Children's HospitalBoston, Egyesült ÁllamokNo longer taking part
- United Hospital CenterBridgeport, Egyesült ÁllamokNo longer taking part
- Maimonides Medical CenterBrooklyn, Egyesült ÁllamokContact: Mahmut Y. Celiker (principal investigator)Résztvevőt keres
- University of Vermont and State Agricultural CollegeBurlington, Egyesült ÁllamokContact: Jessica L. Heath (principal investigator)Résztvevőt keres
- Carson Tahoe Regional Medical CenterCarson City, Egyesült ÁllamokNo longer taking part
- UNC Lineberger Comprehensive Cancer CenterChapel Hill, Egyesült ÁllamokContact: Thomas B. Alexander (principal investigator)Résztvevőt keres
- Vandalia Health/CAMC Institute for Academic MedicineCharleston, Egyesült ÁllamokContact: Mohamad H. Badawi (principal investigator)Résztvevőt keres
- Carolinas Medical Center/Levine Cancer InstituteCharlotte, Egyesült ÁllamokContact: Joel A. Kaplan (principal investigator)Résztvevőt keres
- Lurie Children's Hospital-ChicagoChicago, Egyesült ÁllamokContact: Jenna Rossoff (principal investigator)Résztvevőt keres
- University of Chicago Comprehensive Cancer CenterChicago, Egyesült ÁllamokContact: Gabrielle Lapping-Carr (principal investigator)Résztvevőt keres
- University of IllinoisChicago, Egyesült ÁllamokContact: Dipti S. Dighe (principal investigator)Résztvevőt keres
- Cincinnati Children's Hospital Medical CenterCincinnati, Egyesült ÁllamokContact: Erin H. Breese (principal investigator)Résztvevőt keres
- Rainbow Babies and Childrens HospitalCleveland, Egyesült ÁllamokContact: Duncan S. Stearns (principal investigator)Résztvevőt keres
- Cleveland Clinic FoundationCleveland, Egyesült ÁllamokNo longer taking part
- Prisma Health Richland HospitalColumbia, Egyesült ÁllamokContact: Stuart L. Cramer (principal investigator)Résztvevőt keres
- Nationwide Children's HospitalColumbus, Egyesült ÁllamokContact: Mark A. Ranalli (principal investigator)Résztvevőt keres
- Driscoll Children's HospitalCorpus Christi, Egyesült ÁllamokContact: Nkechi I. Mba (principal investigator)Résztvevőt keres
- Medical City Dallas HospitalDallas, Egyesült ÁllamokContact: Maurizio L. Ghisoli (principal investigator)Résztvevőt keres
- UT Southwestern/Simmons Cancer Center-DallasDallas, Egyesült ÁllamokContact: Tamra L. Slone (principal investigator)Résztvevőt keres
- Geisinger Medical CenterDanville, Egyesült ÁllamokContact: Jagadeesh Ramdas (principal investigator)Résztvevőt keres
- Dayton Children's HospitalDayton, Egyesült ÁllamokContact: Jordan M. Wright (principal investigator)Résztvevőt keres
- Corewell Health Dearborn HospitalDearborn, Egyesült ÁllamokNo longer taking part
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical CenterDenver, Egyesült ÁllamokContact: Florence Choo (principal investigator)Résztvevőt keres
- Blank Children's HospitalDes Moines, Egyesült ÁllamokContact: Samantha L. Mallory (principal investigator)Résztvevőt keres
- Children's Hospital of MichiganDetroit, Egyesült ÁllamokNo longer taking part
- Kaiser Permanente Downey Medical CenterDowney, Egyesült ÁllamokContact: Robert M. Cooper (principal investigator)Résztvevőt keres
- City of Hope Comprehensive Cancer CenterDuarte, Egyesült ÁllamokNo longer taking part
- Duke University Medical CenterDurham, Egyesült ÁllamokContact: Jessica M. Sun (principal investigator)Résztvevőt keres
- Michigan State UniversityEast Lansing, Egyesült ÁllamokNo longer taking part
- El Paso Children's HospitalEl Paso, Egyesült ÁllamokContact: Benjamin Carcamo (principal investigator)Résztvevőt keres
- Inova Fairfax HospitalFalls Church, Egyesült ÁllamokContact: Robin Y. Dulman (principal investigator)Résztvevőt keres
- Sanford Broadway Medical CenterFargo, Egyesült ÁllamokContact: Samuel J. Milanovich (principal investigator)Résztvevőt keres
- Kaiser Permanente-FontanaFontana, Egyesült ÁllamokContact: Robert M. Cooper (principal investigator)Résztvevőt keres
- Golisano Children's Hospital of Southwest FloridaFort Myers, Egyesült ÁllamokContact: Emad K. Salman (principal investigator)Résztvevőt keres
- Cook Children's Medical CenterFort Worth, Egyesült ÁllamokContact: Kenneth M. Heym (principal investigator)Résztvevőt keres
- UF Health Cancer Institute - GainesvilleGainesville, Egyesült ÁllamokContact: Brian Stover (principal investigator)Résztvevőt keres
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's HospitalGrand Rapids, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
- Corewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids, Egyesült ÁllamokNo longer taking part
- Trinity Health Grand Rapids HospitalGrand Rapids, Egyesült ÁllamokNo longer taking part
- Saint Vincent Hospital Cancer Center Green BayGreen Bay, Egyesült ÁllamokContact: Catherine A. Long (principal investigator)Résztvevőt keres
- BI-LO Charities Children's Cancer CenterGreenville, Egyesült ÁllamokContact: Aniket Saha (principal investigator)Résztvevőt keres
- East Carolina UniversityGreenville, Egyesült ÁllamokContact: Andrea R. Whitfield (principal investigator)Résztvevőt keres
- Prisma Health Cancer Institute - EastsideGreenville, Egyesült ÁllamokContact: Aniket Saha (principal investigator)Résztvevőt keres
- Hackensack University Medical CenterHackensack, Egyesült ÁllamokContact: Jing Chen (principal investigator)Résztvevőt keres
- Connecticut Children's Medical CenterHartford, Egyesült ÁllamokContact: Michael S. Isakoff (principal investigator)Résztvevőt keres
- Comprehensive Cancer Centers of Nevada - HendersonHenderson, Egyesült ÁllamokNo longer taking part
- Comprehensive Cancer Centers of Nevada-Horizon RidgeHenderson, Egyesült ÁllamokNo longer taking part
- Comprehensive Cancer Centers of Nevada-Southeast HendersonHenderson, Egyesült ÁllamokNo longer taking part
- Las Vegas Cancer Center-HendersonHenderson, Egyesült ÁllamokNo longer taking part
- Penn State Children's HospitalHershey, Egyesült ÁllamokContact: Lisa M. McGregor (principal investigator)Résztvevőt keres
- Memorial Regional Hospital/Joe DiMaggio Children's HospitalHollywood, Egyesült ÁllamokContact: Iftikhar Hanif (principal investigator)Résztvevőt keres
- Kapiolani Medical Center for Women and ChildrenHonolulu, Egyesült ÁllamokContact: Wade T. Kyono (principal investigator)Résztvevőt keres
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston, Egyesült ÁllamokContact: Anil George (principal investigator)Résztvevőt keres
- UT MD Anderson Cancer CenterHouston, Egyesült ÁllamokContact: Najat C. Daw (principal investigator)Résztvevőt keres
- Ascension Saint Vincent Indianapolis HospitalIndianapolis, Egyesült ÁllamokContact: Bassem I. Razzouk (principal investigator)Résztvevőt keres
- Riley Hospital for ChildrenIndianapolis, Egyesült ÁllamokContact: Sandeep Batra (principal investigator)Résztvevőt keres
- University of Iowa/Holden Comprehensive Cancer CenterIowa City, Egyesült ÁllamokContact: Andrew P. Groves (principal investigator)Résztvevőt keres
- University of Mississippi Medical CenterJackson, Egyesült ÁllamokContact: Amanda Strobel (principal investigator)Résztvevőt keres
- Nemours Children's Clinic-JacksonvilleJacksonville, Egyesült ÁllamokContact: Emi H. Caywood (principal investigator)Résztvevőt keres
- Bronson Methodist HospitalKalamazoo, Egyesült ÁllamokContact: Kathleen Y. Butler (principal investigator)Résztvevőt keres
- Beacon KalamazooKalamazoo, Egyesült ÁllamokNo longer taking part
- West Michigan Cancer CenterKalamazoo, Egyesült ÁllamokNo longer taking part
- Children's Mercy Hospitals and ClinicsKansas City, Egyesült ÁllamokContact: Keith J. August (principal investigator)Résztvevőt keres
- Kingman Regional Medical CenterKingman, Egyesült ÁllamokNo longer taking part
- East Tennessee Childrens HospitalKnoxville, Egyesült ÁllamokContact: Susan E. Spiller (principal investigator)Résztvevőt keres
- Alliance for Childhood Diseases/Cure 4 the Kids FoundationLas Vegas, Egyesült ÁllamokContact: Joseph L. Lasky (principal investigator)Résztvevőt keres
- Summerlin Hospital Medical CenterLas Vegas, Egyesült ÁllamokContact: Joseph L. Lasky (principal investigator)Résztvevőt keres
- Ann M Wierman MD LTDLas Vegas, Egyesült ÁllamokNo longer taking part
- Comprehensive Cancer Centers of NevadaLas Vegas, Egyesült ÁllamokNo longer taking part
- Comprehensive Cancer Centers of Nevada - Central ValleyLas Vegas, Egyesült ÁllamokNo longer taking part
- Comprehensive Cancer Centers of Nevada - NorthwestLas Vegas, Egyesült ÁllamokNo longer taking part
- Comprehensive Cancer Centers of Nevada - Town CenterLas Vegas, Egyesült ÁllamokNo longer taking part
- Comprehensive Cancer Centers of Nevada-SummerlinLas Vegas, Egyesült ÁllamokNo longer taking part
- Hope Cancer Care of NevadaLas Vegas, Egyesült ÁllamokNo longer taking part
- Las Vegas Cancer Center-Medical CenterLas Vegas, Egyesült ÁllamokNo longer taking part
- OptumCare Cancer Care at CharlestonLas Vegas, Egyesült ÁllamokNo longer taking part
- OptumCare Cancer Care at Fort ApacheLas Vegas, Egyesült ÁllamokNo longer taking part
- OptumCare Cancer Care at MountainViewLas Vegas, Egyesült ÁllamokNo longer taking part
- Sunrise Hospital and Medical CenterLas Vegas, Egyesült ÁllamokNo longer taking part
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon, Egyesült ÁllamokContact: Angela Ricci (principal investigator)Résztvevőt keres
- University of Kentucky/Markey Cancer CenterLexington, Egyesült ÁllamokContact: James T. Badgett (principal investigator)Résztvevőt keres
- Arkansas Children's HospitalLittle Rock, Egyesült ÁllamokContact: Michael W. Bishop (principal investigator)Résztvevőt keres
- Loma Linda University Medical CenterLoma Linda, Egyesült ÁllamokContact: Albert Kheradpour (principal investigator)Résztvevőt keres
- Miller Children's and Women's Hospital Long BeachLong Beach, Egyesült ÁllamokContact: Jacqueline N. Casillas (principal investigator)Résztvevőt keres
- Cedars-Sinai Medical CenterLos Angeles, Egyesült ÁllamokContact: Nicole M. Baca (principal investigator)Résztvevőt keres
- Children's Hospital Los AngelesLos Angeles, Egyesült ÁllamokContact: Jamie L. Stokke (principal investigator)Résztvevőt keres
- Mattel Children's Hospital UCLALos Angeles, Egyesült ÁllamokContact: Satiro N. De Oliveira (principal investigator)Résztvevőt keres
- Kaiser Permanente Los Angeles Medical CenterLos Angeles, Egyesült ÁllamokNo longer taking part
- Norton Children's HospitalLouisville, Egyesült ÁllamokContact: Michael J. Ferguson (principal investigator)Résztvevőt keres
- Covenant Children's HospitalLubbock, Egyesült ÁllamokContact: Kishor M. Bhende (principal investigator)Résztvevőt keres
- UMC Cancer Center / UMC Health SystemLubbock, Egyesült ÁllamokContact: Erin K. Barr (principal investigator)Résztvevőt keres
- Valley Children's HospitalMadera, Egyesült ÁllamokContact: Ruetima Titapiwatanakun (principal investigator)Résztvevőt keres
- University of Wisconsin Carbone Cancer Center - University HospitalMadison, Egyesült ÁllamokContact: Cathy A. Lee-Miller (principal investigator)Résztvevőt keres
- WVUH-Berkely Medical CenterMartinsburg, Egyesült ÁllamokNo longer taking part
- Loyola University Medical CenterMaywood, Egyesült ÁllamokContact: Eugene Suh (principal investigator)Résztvevőt keres
- Banner Children's at DesertMesa, Egyesült ÁllamokContact: Joseph C. Torkildson (principal investigator)Résztvevőt keres
- Children's Hospital of WisconsinMilwaukee, Egyesült ÁllamokContact: Michael J. Burke (principal investigator)Résztvevőt keres
- NYU Langone Hospital - Long IslandMineola, Egyesült ÁllamokContact: Chana L. Glasser (principal investigator)Résztvevőt keres
- Children's Hospitals and Clinics of Minnesota - MinneapolisMinneapolis, Egyesült ÁllamokContact: Michael K. Richards (principal investigator)Résztvevőt keres
- University of Minnesota/Masonic Cancer CenterMinneapolis, Egyesült ÁllamokContact: Peter M. Gordon (principal investigator)Résztvevőt keres
- USA Health Strada Patient Care CenterMobile, Egyesült ÁllamokContact: Hamayun Imran (principal investigator)Résztvevőt keres
- West Virginia University HealthcareMorgantown, Egyesült ÁllamokContact: Ashley E. Meyer (principal investigator)Résztvevőt keres
- Morristown Medical CenterMorristown, Egyesült ÁllamokContact: Kathryn L. Laurie (principal investigator)Résztvevőt keres
- Trinity Health Muskegon HospitalMuskegon, Egyesült ÁllamokNo longer taking part
- The Children's Hospital at TriStar CentennialNashville, Egyesült ÁllamokContact: Clinton M. Carroll (principal investigator)Résztvevőt keres
- Vanderbilt University/Ingram Cancer CenterNashville, Egyesült ÁllamokContact: Brianna N. Smith (principal investigator)Résztvevőt keres
- Rutgers Cancer Institute of New JerseyNew Brunswick, Egyesült ÁllamokContact: Richard A. Drachtman (principal investigator)Résztvevőt keres
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University HospitalNew Brunswick, Egyesült ÁllamokContact: Richard A. Drachtman (principal investigator)Résztvevőt keres
- Saint Peter's University HospitalNew Brunswick, Egyesült ÁllamokContact: Nibal A. Zaghloul (principal investigator)Résztvevőt keres
- The Steven and Alexandra Cohen Children's Medical Center of New YorkNew Hyde Park, Egyesült ÁllamokContact: Julie I. Krystal (principal investigator)Résztvevőt keres
- Children's Hospital New OrleansNew Orleans, Egyesült ÁllamokContact: Maria C. Velez-Yanguas (principal investigator)Résztvevőt keres
- Ochsner Medical Center JeffersonNew Orleans, Egyesült ÁllamokNo longer taking part
- Laura and Isaac Perlmutter Cancer Center at NYU LangoneNew York, Egyesült ÁllamokContact: Elizabeth A. Raetz (principal investigator)Résztvevőt keres
- Memorial Sloan-Kettering Cancer CenterNew York, Egyesült ÁllamokContact: Kavitha Ramaswamy (principal investigator)Résztvevőt keres
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York, Egyesült ÁllamokContact: Nobuko Hijiya (principal investigator)Résztvevőt keres
- NYP/Weill Cornell Medical CenterNew York, Egyesült ÁllamokContact: Jaclyn Rosenzweig (principal investigator)Résztvevőt keres
- Newark Beth Israel Medical CenterNewark, Egyesült ÁllamokContact: Teena Bhatla (principal investigator)Résztvevőt keres
- Corewell Health Lakeland Hospitals - Niles HospitalNiles, Egyesült ÁllamokNo longer taking part
- Children's Hospital of The King's DaughtersNorfolk, Egyesült ÁllamokContact: Melissa S. Mark (principal investigator)Résztvevőt keres
- Cancer and Hematology Centers of Western Michigan - Norton ShoresNorton Shores, Egyesült ÁllamokNo longer taking part
- Kaiser Permanente-OaklandOakland, Egyesült ÁllamokContact: Aarati V. Rao (principal investigator)Résztvevőt keres
- University of Oklahoma Health Sciences CenterOklahoma City, Egyesült ÁllamokContact: Rene Y. McNall-Knapp (principal investigator)Résztvevőt keres
- Children's Hospital and Medical Center of OmahaOmaha, Egyesült ÁllamokContact: Jill C. Beck (principal investigator)Résztvevőt keres
- University of Nebraska Medical CenterOmaha, Egyesült ÁllamokContact: Jill C. Beck (principal investigator)Résztvevőt keres
- Children's Hospital of Orange CountyOrange, Egyesült ÁllamokContact: Elyssa M. Rubin (principal investigator)Résztvevőt keres
- AdventHealth OrlandoOrlando, Egyesült ÁllamokContact: Fouad M. Hajjar (principal investigator)Résztvevőt keres
- Arnold Palmer Hospital for ChildrenOrlando, Egyesült ÁllamokContact: Jaime M. Libes-Bander (principal investigator)Résztvevőt keres
- Nemours Children's HospitalOrlando, Egyesült ÁllamokContact: Emi H. Caywood (principal investigator)Résztvevőt keres
- Hope Cancer Care of Nevada-PahrumpPahrump, Egyesült ÁllamokNo longer taking part
- Lucile Packard Children's Hospital Stanford UniversityPalo Alto, Egyesült ÁllamokContact: Jay Michael S. Balagtas (principal investigator)Résztvevőt keres
- Camden Clark Medical CenterParkersburg, Egyesült ÁllamokNo longer taking part
- Saint Joseph's Regional Medical CenterPaterson, Egyesült ÁllamokContact: Alissa Kahn (principal investigator)Résztvevőt keres
- Nemours Children's Clinic - PensacolaPensacola, Egyesült ÁllamokContact: Jeffrey H. Schwartz (principal investigator)Résztvevőt keres
- Sacred Heart HospitalPensacola, Egyesült ÁllamokNo longer taking part
- OSF Children's Hospital of IllinoisPeoria, Egyesült ÁllamokContact: Prerna Kumar (principal investigator)Résztvevőt keres
- Children's Hospital of PhiladelphiaPhiladelphia, Egyesült ÁllamokContact: Shannon L. Maude (principal investigator)Résztvevőt keres
- Saint Christopher's Hospital for ChildrenPhiladelphia, Egyesült ÁllamokContact: Gregory E. Halligan (principal investigator)Résztvevőt keres
- Phoenix Childrens HospitalPhoenix, Egyesült ÁllamokContact: Dana B. Salzberg (principal investigator)Résztvevőt keres
- Children's Hospital of Pittsburgh of UPMCPittsburgh, Egyesült ÁllamokContact: Jenny Ruiz (principal investigator)Résztvevőt keres
- Legacy Emanuel Children's HospitalPortland, Egyesült ÁllamokContact: Jason M. Glover (principal investigator)Résztvevőt keres
- Oregon Health and Science UniversityPortland, Egyesült ÁllamokContact: Bill H. Chang (principal investigator)Résztvevőt keres
- Rhode Island HospitalProvidence, Egyesült ÁllamokContact: Bradley DeNardo (principal investigator)Résztvevőt keres
- Corewell Health Reed City HospitalReed City, Egyesült ÁllamokNo longer taking part
- Renown Regional Medical CenterReno, Egyesült ÁllamokContact: Seema L. Rao (principal investigator)Résztvevőt keres
- Cancer Care Specialists RenoReno, Egyesült ÁllamokNo longer taking part
- Saint Mary's Regional Medical CenterReno, Egyesült ÁllamokNo longer taking part
- Valley Medical CenterRenton, Egyesült ÁllamokNo longer taking part
- VCU Massey Comprehensive Cancer CenterRichmond, Egyesült ÁllamokContact: Jordyn R. Griffin (principal investigator)Résztvevőt keres
- University of RochesterRochester, Egyesült ÁllamokNo longer taking part
- Corewell Health Children'sRoyal Oak, Egyesült ÁllamokContact: Marie V. Nelson (principal investigator)Résztvevőt keres
- Corewell Health William Beaumont University HospitalRoyal Oak, Egyesült ÁllamokNo longer taking part
- Sutter Medical Center SacramentoSacramento, Egyesült ÁllamokContact: Sandra Baril (principal investigator)Résztvevőt keres
- University of California Davis Comprehensive Cancer CenterSacramento, Egyesült ÁllamokContact: Marcio H. Malogolowkin (principal investigator)Résztvevőt keres
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer CenterSaint Joseph, Egyesült ÁllamokNo longer taking part
- Corewell Health Lakeland Hospitals - Saint Joseph HospitalSaint Joseph, Egyesült ÁllamokNo longer taking part
- Primary Children's HospitalSalt Lake City, Egyesült ÁllamokContact: Luke D. Maese (principal investigator)Résztvevőt keres
- Children's Hospital of San AntonioSan Antonio, Egyesült ÁllamokContact: Julie Voeller (principal investigator)Résztvevőt keres
- Methodist Children's Hospital of South TexasSan Antonio, Egyesült ÁllamokContact: Jose M. Esquilin (principal investigator)Résztvevőt keres
- University of Texas Health Science Center at San AntonioSan Antonio, Egyesült ÁllamokContact: Anne-Marie R. Langevin (principal investigator)Résztvevőt keres
- Kaiser Permanente-San Diego ZionSan Diego, Egyesült ÁllamokContact: Robert M. Cooper (principal investigator)Résztvevőt keres
- Rady Children's Hospital - San DiegoSan Diego, Egyesült ÁllamokContact: William D. Roberts (principal investigator)Résztvevőt keres
- UCSF Medical Center-Mission BaySan Francisco, Egyesült ÁllamokContact: Karen R. Rabin (principal investigator)Résztvevőt keres
- Memorial Health University Medical CenterSavannah, Egyesült ÁllamokContact: James N. Yarnall (principal investigator)Résztvevőt keres
- Maine Children's Cancer ProgramScarborough, Egyesült ÁllamokContact: Eric C. Larsen (principal investigator)Résztvevőt keres
- Seattle Children's HospitalSeattle, Egyesült ÁllamokContact: Sarah E. Leary (principal investigator)Résztvevőt keres
- Sanford USD Medical Center - Sioux FallsSioux Falls, Egyesült ÁllamokContact: Jordan Fritch-Hanson (principal investigator)Résztvevőt keres
- Providence Sacred Heart Medical Center and Children's HospitalSpokane, Egyesült ÁllamokContact: Judy L. Felgenhauer (principal investigator)Résztvevőt keres
- Cardinal Glennon Children's Medical CenterSt Louis, Egyesült ÁllamokContact: William S. Ferguson (principal investigator)Résztvevőt keres
- Mercy Hospital Saint LouisSt Louis, Egyesült ÁllamokContact: Robin D. Hanson (principal investigator)Résztvevőt keres
- Washington University School of MedicineSt Louis, Egyesült ÁllamokContact: Kristin Zorn (principal investigator)Résztvevőt keres
- Johns Hopkins All Children's HospitalSt. Petersburg, Egyesült ÁllamokContact: Jennifer L. Mayer (principal investigator)Résztvevőt keres
- Stony Brook University Medical CenterStony Brook, Egyesült ÁllamokContact: Laura E. Hogan (principal investigator)Résztvevőt keres
- ProMedica Flower HospitalSylvania, Egyesült ÁllamokNo longer taking part
- State University of New York Upstate Medical UniversitySyracuse, Egyesült ÁllamokContact: Melanie A. Comito (principal investigator)Résztvevőt keres
- Madigan Army Medical CenterTacoma, Egyesült ÁllamokContact: Melissa A. Forouhar (principal investigator)Résztvevőt keres
- Mary Bridge Children's Hospital and Health CenterTacoma, Egyesült ÁllamokContact: Robert G. Irwin (principal investigator)Résztvevőt keres
- Saint Joseph's Hospital/Children's Hospital-TampaTampa, Egyesült ÁllamokContact: Don E. Eslin (principal investigator)Résztvevőt keres
- Tampa General HospitalTampa, Egyesült ÁllamokContact: Andrew J. Galligan (principal investigator)Résztvevőt keres
- Montefiore Medical Center - Moses CampusThe Bronx, Egyesült ÁllamokContact: Alice Lee (principal investigator)Résztvevőt keres
- ProMedica Toledo Hospital/Russell J Ebeid Children's HospitalToledo, Egyesült ÁllamokContact: Jamie L. Dargart (principal investigator)Résztvevőt keres
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTorrance, Egyesült ÁllamokNo longer taking part
- Munson Medical CenterTraverse City, Egyesült ÁllamokNo longer taking part
- Corewell Health Beaumont Troy HospitalTroy, Egyesült ÁllamokNo longer taking part
- Banner University Medical Center - TucsonTucson, Egyesült ÁllamokContact: Monica M. Davini (principal investigator)Résztvevőt keres
- Saint Francis Children's HospitalTulsa, Egyesült ÁllamokContact: Jill A. Salo (principal investigator)Résztvevőt keres
- Children's National Medical CenterWashington D.C., Egyesült ÁllamokContact: Jeffrey S. Dome (principal investigator)Résztvevőt keres
- MedStar Georgetown University HospitalWashington D.C., Egyesült ÁllamokContact: Caileigh Pudela (principal investigator)Résztvevőt keres
- Saint Mary's Medical CenterWest Palm Beach, Egyesült ÁllamokContact: Matthew D. Ramirez (principal investigator)Résztvevőt keres
- Alfred I duPont Hospital for ChildrenWilmington, Egyesült ÁllamokContact: Emi H. Caywood (principal investigator)Résztvevőt keres
- Wake Forest University Health SciencesWinston-Salem, Egyesült ÁllamokContact: Sarah Supples (principal investigator)Résztvevőt keres
- University of Michigan Health - WestWyoming, Egyesült ÁllamokNo longer taking part
- North Star Lodge Cancer Center at Yakima Valley Memorial HospitalYakima, Egyesült ÁllamokNo longer taking part
A vizsgálatról
Mit akar kideríteni a vizsgálat
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
A vizsgálat 9 csoportja
- Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patientsA vizsgált kezelés
Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with \< 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD \<0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
Kezelés: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate és Nivolumab
- Group 1, Arm A (dexamethasone, blinatumomab, MTX)A vizsgált kezelés
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given \< 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD \< 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD \>= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024)
Kezelés: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture és Methotrexate
- Group 1, Arm B (dexamethasone, blinatumomab, MTX)A vizsgált kezelés
Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD \< 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD \>= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024)
Kezelés: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate és Nivolumab
- Group 2, Arm C (dexamethasone, blinatumomab, MTX)A vizsgált kezelés
Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given \< 7 days prior to the start of this cycle). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD \< 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD \>= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024)
Kezelés: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Dexamethasone, Lumbar Puncture és Methotrexate
- Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX)A vizsgált kezelés
Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD \< 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD \>= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024)
Kezelés: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Dexamethasone, Lumbar Puncture, Methotrexate és Nivolumab
- Group 3, Arm E (dexamethasone, blinatumomab, MTX)A vizsgált kezelés
See Outline section
Kezelés: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase és Vincristine Sulfate
- Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)A vizsgált kezelés
See Outline section
Kezelés: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase és Vincristine Sulfate
- Group 4 Arm I (Dexamethasone, blinatumomab, nivolumab)A vizsgált kezelés
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with \< 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
Kezelés: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate és Nivolumab
- Group 4, Arm H (dexamethasone blinatumomab)A vizsgált kezelés
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with \< 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
Kezelés: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture és Methotrexate
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- Kérdések a feltételekről
- Forrás: NCT04546399: ki vehet részt
- Publikációk
- Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.Journal of the National Comprehensive Cancer Network : JNCCN, 2025
- Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.Hematology (Amsterdam, Netherlands), 2022
- A regiszteradat frissítve
- 2026. november 12.